252 related articles for article (PubMed ID: 24033119)
1. Marine natural products: bryostatins in preclinical and clinical studies.
Kollár P; Rajchard J; Balounová Z; Pazourek J
Pharm Biol; 2014 Feb; 52(2):237-42. PubMed ID: 24033119
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
3. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
4. The Phylum Bryozoa as a Promising Source of Anticancer Drugs.
Figuerola B; Avila C
Mar Drugs; 2019 Aug; 17(8):. PubMed ID: 31426556
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
6. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
7. Review of bioactive secondary metabolites from marine bryozoans in the progress of new drugs discovery.
Tian XR; Tang HF; Tian XL; Hu JJ; Huang LL; Gustafson KR
Future Med Chem; 2018 Jun; 10(12):1497-1514. PubMed ID: 29788787
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
9. The medicinal potential of promising marine macrolides with anticancer activity.
Qi Y; Ma S
ChemMedChem; 2011 Mar; 6(3):399-409. PubMed ID: 21302362
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of selected natural products as therapeutic agents against cancer.
Banerjee S; Wang Z; Mohammad M; Sarkar FH; Mohammad RM
J Nat Prod; 2008 Mar; 71(3):492-6. PubMed ID: 18302335
[TBL] [Abstract][Full Text] [Related]
12. Co-induction of lymphokine synthesis by the antineoplastic bryostatins.
Mohr H; Pettit GR; Plessing-Menze A
Immunobiology; 1987 Nov; 175(5):420-30. PubMed ID: 3123367
[TBL] [Abstract][Full Text] [Related]
13. "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo.
DeChristopher BA; Fan AC; Felsher DW; Wender PA
Oncotarget; 2012 Jan; 3(1):58-66. PubMed ID: 22308267
[TBL] [Abstract][Full Text] [Related]
14. Isolation, analytical measurements, and cell line studies of the iron-bryostatin-1 complex.
Plummer S; Manning T; Baker T; McGreggor T; Patel M; Wylie G; Phillips D
Bioorg Med Chem Lett; 2016 May; 26(10):2489-2497. PubMed ID: 27068183
[TBL] [Abstract][Full Text] [Related]
15. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
16. Effects of bryostatins 1 and 2 on morphological and functional differentiation of SH-SY5Y human neuroblastoma cells.
Jalava AM; Heikkilä J; Akerlind G; Pettit GR; Akerman KE
Cancer Res; 1990 Jun; 50(11):3422-8. PubMed ID: 2334938
[TBL] [Abstract][Full Text] [Related]
17. Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications.
Wu R; Chen H; Chang N; Xu Y; Jiao J; Zhang H
Chemistry; 2020 Jan; 26(6):1166-1195. PubMed ID: 31479550
[TBL] [Abstract][Full Text] [Related]
18. Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.
Baryza JL; Brenner SE; Craske ML; Meyer T; Wender PA
Chem Biol; 2004 Sep; 11(9):1261-7. PubMed ID: 15380186
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway.
Staveness D; Abdelnabi R; Near KE; Nakagawa Y; Neyts J; Delang L; Leyssen P; Wender PA
J Nat Prod; 2016 Apr; 79(4):680-4. PubMed ID: 26900711
[TBL] [Abstract][Full Text] [Related]
20. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
